kabutan

Astellas Pharma Inc.(4503) Summary

4503
TSE Prime
Astellas Pharma Inc.
2,127.5
JPY
-4.5
(-0.21%)
Jan 29, 3:30 pm JST
13.90
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
2,130
Jan 29, 6:09 pm JST
Summary Chart Historical News Financial Result
PER
21.1
PBR
2.36
Yield
3.67%
Margin Trading Ratio
30.74
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
2,101.5 JPY 13.72 USD
Previous Close Jan 28
2,132.0 JPY 13.96 USD
High Jan 29, 2:05 pm
2,148.5 JPY 14.04 USD
Low Jan 29, 9:07 am
2,080.5 JPY 13.59 USD
Volume
8,756,200
Trading Value
0.02T JPY 0.12B USD
VWAP
2120.48 JPY 13.86 USD
Minimum Trading Value
212,750 JPY 1,390 USD
Market Cap
3.85T JPY 0.03T USD
Number of Trades
9,922
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
6,367
1-Year High Feb 12, 2025
24,753
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 612,700 946,200 1.54
Jan 16, 2026 669,600 988,900 1.48
Jan 9, 2026 674,600 904,200 1.34
Dec 26, 2025 657,100 1,140,300 1.74
Dec 19, 2025 677,500 1,182,500 1.75
Company Profile
Astellas Pharma Inc. is the second-largest pharmaceutical company in Japan, specializing in innovative drugs. The company has particular strengths in urology and transplantation, and is focusing on anticancer drugs.
Sector
Pharmaceuticals
Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company's main business is the research and development, manufacturing, and sales of pharmaceuticals, with operations spanning globally. In research and development, Astellas focuses on cutting-edge fields such as regenerative medicine and gene therapy, primarily through its U.S. subsidiaries. The company has 11 production sites worldwide, including in Ireland, the Netherlands, and China. Its sales network covers approximately 70 countries where it conducts direct sales, including the United States, Germany, China, France, Spain, and South Korea. Astellas has established an integrated pharmaceutical business across its group, collaborating with regional affiliates to supply raw materials and products. The company operates in a single business segment - pharmaceuticals - leveraging its global R&D infrastructure and sales network for business expansion.